Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
作者:M. Mark midland、Alfonso tramontano、Aleksander kazubski、Richard S. graham、David J.S. tsai、Daniel B. cardin
DOI:10.1016/s0040-4020(01)82422-4
日期:1984.1
Propargyl ketones are readily reduced by the asymmetric reducing agent B-3-pinanyl-9- borabicyclo[3.3.1]-nonane (Alpine-borane). The reagent prepared from (+)-α-pinene and 9-BBN provides the R enantiomer while the S enantiomer can be obtained from (-)-α-pinene. Alternatively the S enantiomer can be prepared from the reagent derived from 9-BBN and the benzyl ether of nopol (6,6-dimethyl-bicyclo[3.11
Kinetic Resolution of Propargylic Alcohols Catalyzed by Benzotetramisole
作者:Vladimir B. Birman、Lei Guo
DOI:10.1021/ol061906y
日期:2006.10.1
[reaction: see text] Kineticresolution of variously substituted secondary propargylic alcoholscatalyzed by benzotetramisole (BTM) proceeds with selectivity factors up to 32, the highest ever achieved with nonenzymatic catalysts for this class of substrates.
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
申请人:Ren Pingda
公开号:US20090312319A1
公开(公告)日:2009-12-17
Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS
申请人:Ren Pingda
公开号:US20110046165A1
公开(公告)日:2011-02-24
Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein.